Flasar MH - Search Results

1

Disparities in the use of immunomodulators and biologics for the treatment of inflammatory bowel disease: a retrospective cohort study.

Flasar MH, Johnson T, Roghmann MC, Cross RK. Flasar MH, et al. Inflamm Bowel Dis. 2008 Jan;14(1):13-9. doi: 10.1002/ibd.20298. Inflamm Bowel Dis. 2008. PMID: 17973305

2

Racial differences in disease extent and severity in patients with ulcerative colitis: a retrospective cohort study.

Flasar MH, Quezada S, Bijpuria P, Cross RK. Flasar MH, et al. Dig Dis Sci. 2008 Oct;53(10):2754-60. doi: 10.1007/s10620-007-0190-x. Epub 2008 Feb 14. Dig Dis Sci. 2008. PMID: 18273704

3

Outcome of medical treatment of stricturing and penetrating Crohn's disease: a retrospective study.

Samimi R, Flasar MH, Kavic S, Tracy K, Cross RK. Samimi R, et al. Among authors: flasar mh. Inflamm Bowel Dis. 2010 Jul;16(7):1187-94. doi: 10.1002/ibd.21160. Inflamm Bowel Dis. 2010. PMID: 19902541

4

Anti-TNF therapy is associated with decreased imaging and radiation exposure in patients with Crohn's disease.

Patil SA, Rustgi A, Quezada SM, Flasar MH, Vandermeer F, Cross RK. Patil SA, et al. Among authors: flasar mh. Inflamm Bowel Dis. 2013 Jan;19(1):92-8. doi: 10.1002/ibd.22982. Inflamm Bowel Dis. 2013. PMID: 22508292

5

Step up versus early biologic therapy for Crohn's disease in clinical practice.

Ghazi LJ, Patil SA, Rustgi A, Flasar MH, Razeghi S, Cross RK. Ghazi LJ, et al. Among authors: flasar mh. Inflamm Bowel Dis. 2013 Jun;19(7):1397-403. doi: 10.1097/MIB.0b013e318281337d. Inflamm Bowel Dis. 2013. PMID: 23598813

6

Racial differences in disease activity and quality of life in patients with Crohn's disease.

Ghazi LJ, Lydecker AD, Patil SA, Rustgi A, Cross RK, Flasar MH. Ghazi LJ, et al. Among authors: flasar mh. Dig Dis Sci. 2014 Oct;59(10):2508-13. doi: 10.1007/s10620-014-3141-3. Epub 2014 Apr 10. Dig Dis Sci. 2014. PMID: 24718861

7

Biological and Immunomodulator Use in Crohn's Disease in a Medicaid Population.

Flasar MH, Chao J, Ozbay AB, Skup M, Lu M, Cross R. Flasar MH, et al. Inflamm Bowel Dis. 2016 May;22(5):1056-64. doi: 10.1097/MIB.0000000000000730. Inflamm Bowel Dis. 2016. PMID: 26914436

8

Current and future role of serogenomics in ulcerative colitis.

Flasar MH, Cross RK, Doman DB. Flasar MH, et al. Gastroenterol Hepatol (N Y). 2011 Nov;7(11):720-7. Gastroenterol Hepatol (N Y). 2011. PMID: 22298968 Free PMC article.

9

Anti-tumor necrosis factor therapy is associated with infections after abdominal surgery in Crohn's disease patients.

Syed A, Cross RK, Flasar MH. Syed A, et al. Among authors: flasar mh. Am J Gastroenterol. 2013 Apr;108(4):583-93. doi: 10.1038/ajg.2012.464. Epub 2013 Mar 12. Am J Gastroenterol. 2013. PMID: 23481144

10

Reduced Imaging Radiation Exposure and Costs Associated with Anti-Tumor Necrosis Factor Therapy in Crohn's Disease.

Patil SA, Flasar MH, Lin J, Lingohr-Smith M, Skup M, Wang S, Chao J, Cross RK. Patil SA, et al. Among authors: flasar mh. Dig Dis Sci. 2019 Jan;64(1):60-67. doi: 10.1007/s10620-018-5322-y. Epub 2018 Oct 11. Dig Dis Sci. 2019. PMID: 30311154

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

25 results

Search Page

Filters